Karyopharm estimates FY2024 total rev ~$145M; Phase 3 MF data in 2H 2025

Karyopharm Therapeutics Inc.

2024-FY EPS reported -$0.93 revenue$145,237,000

Preliminary FY2024 total revenue ~$145M, XPOVIO net product rev ~$113M; Q4 rev ~$30M, XPOVIO ~$29M.
Phase 3 SENTRY trial (selinexor+ruxolitinib in MF) enrollment completion in 1H 2025, top-line data in 2H 2025.
Appointed Lori Macomber as CFO (Jan 3, 2025) and Brendan Strong as SVP IR (Dec 9, 2024).
Cash, equivalents, and investments ~$109M as of Dec 31, 2024; expected runway into Q1 2026 (excl. note repayment).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.